Quick Answer
CRISPR Therapeutics AG reported Common Stock Shares Outstanding of 95.89 million shares for the year ending 2025.
- CRISPR Therapeutics AG showed an increase of +11.8% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from CRISPR Therapeutics AG's annual report (Form 10-K), filed with the SEC on February 12, 2026.
- XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 11 years of available data (2015 to 2025), CRISPR Therapeutics AG's Common Stock Shares Outstanding has grown by 1,634.7%.
- Historical annual values: Fiscal year 2025: 95.89 million shares | Fiscal year 2024: 85.74 million shares | Fiscal year 2023: 80.04 million shares | Fiscal year 2022: 78.51 million shares | Fiscal year 2021: 76.99 million shares | Fiscal year 2020: 73.91 million shares | Fiscal year 2019: 60.78 million shares | Fiscal year 2018: 51.85 million shares | Fiscal year 2017: 40.59 million shares | Fiscal year 2016: 39.72 million shares | Fiscal year 2015: 5.53 million shares.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: